Using safe, affordable and accessible non‐steroidal anti‐inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract

• Published in: Journal of the International AIDS Society 2018-07, Vol.21 (7), p.e25150-n/a
• Main Authors: Lajoie, Julie, Birse, Kenzie, Mwangi, Lucy, Chen, Yufei, Cheruiyot, Juliana, Akolo, Maureen, Mungai, John, Boily‐Larouche, Genevieve, Romas, Laura, Mutch, Sarah, Kimani, Makobu, Oyugi, Julius, Ho, Emmanuel A, Burgener, Adam, Kimani, Joshua, Fowke, Keith R
• Format: Article
• Language: English
• Subjects: Abdomen; acetylsalicylic acid; Acquired immune deficiency syndrome; Adult; AIDS; Anti-inflammatory agents; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Aspirin; Aspirin - therapeutic use; Cytokines; Disease prevention; Dosage and administration; Drug therapy; Drugs; Female; Female genitalia; Flow cytometry; Genitalia, Female - cytology; Genitalia, Female - drug effects; Genitalia, Female - immunology; Genotype & phenotype; HIV; HIV infections; HIV Infections - pathology; HIV Infections - prevention & control; HIV prevention; HIV target cells; HIV‐exposed seronegative (HESN); Human immunodeficiency virus; Humans; hydroxychloroquine; Hydroxychloroquine - therapeutic use; immune activation; immune quiescence; Infections; Inflammation; Kenya; Laboratories; Mucous Membrane - virology; NK Cell Lectin-Like Receptor Subfamily B; Pain; Pilot Projects; Prevention; Proteomics; Risk factors; Safety and security measures; Sex industry; Sex Workers; T cells; T-Lymphocytes
• ISSN: 1758-2652; 1758-2652
• DOI: 10.1002/jia2.25150

Introduction At its basic level, HIV infection requires a replication‐competent virus and a susceptible target cell. Elevated levels of vaginal inflammation has been associated with the increased risk of HIV infection as it brings highly activated HIV target cells (CCR5+CD4+ T cells; CCR5+CD4+CD161+ Th17 T cells) to the female genital tract (FGT) where they interact with HIV. Decreased HIV risk has been associated with a phenotype of decreased immune activation, called immune quiescence, described among Kenyan female sex workers who were intensely exposed to HIV yet remain uninfected. Current prevention approaches focus on limiting viral access. We took the novel HIV prevention approach of trying to limit the number of HIV target cells in the genital tract by reducing inflammation using safe, affordable and globally accessible anti‐inflammatory drugs. Methods We hypothesized that the daily administration of low doses of acetylsalicylic acid (ASA 81 mg) or hydroxychloroquine (HCQ 200 mg) would reduce inflammation thereby decreasing HIV target cells at the FGT. Low‐risk HIV seronegative women from Nairobi, Kenya were randomized for six weeks therapy of ASA (n = 37) or HCQ (n = 39) and tested to determine the impact on their systemic and mucosal immune environment. Results The results showed that HCQ use was associated with a significant reduction in the proportion of systemic T cells that were CCR5+CD4+ (p = 0.01) and Th17 (p = 0.01). In the ASA arm, there was a 35% and 28% decrease in the proportion of genital T cells that were CD4+CCR5+ (p = 0.017) and Th17 (p = 0.04) respectively. Proteomic analyses of the cervical lavage showed ASA use was associated with significantly reduced amount of proteins involved in the inflammatory response and cell recruitment at the mucosa, although none of the individual proteins passed multiple comparison correction. These changes were more apparent in women with Lactobacillus dominant microbiomes. Conclusion Together, these data indicate that taking low‐dose ASA daily was associated with significant reduction in HIV target cells at the FGT. This study provides proof‐of‐concept for a novel HIV‐prevention approach that reducing inflammation using safe, affordable and globally accessible non‐steroidal anti‐inflammatory agents is associated with significant reduction in the proportion of HIV‐target cells at the FGT.